(redirected from Best Supportive Care)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.


Watchful attention; custody; diligence; concern; caution; as opposed to Negligence or carelessness.

In the law of negligence, the standard of reasonable conduct determines the amount of care to be exercised in a situation. The care taken must be proportional to the apparent risk. As danger increases, commensurate caution must be observed.

Slight care is the care persons of ordinary prudence generally exercise in regard to their personal affairs of minimal importance.

Reasonable care, also known as ordinary care, is the degree of care, diligence, or precaution that may fairly, ordinarily, and properly be expected or required in consideration of the nature of the action, the subject matter, and the surrounding circumstances.

Great care is the degree of care that persons of ordinary prudence usually exercise with respect to their personal affairs of great importance.

Another type of care is that which a fiduciary—a person having a duty, created by his or her undertaking, to act primarily for another's benefit—exercises in regard to valuable possessions entrusted to him or her by another.

West's Encyclopedia of American Law, edition 2. Copyright 2008 The Gale Group, Inc. All rights reserved.


n. in law, to be attentive, prudent and vigilant. Essentially, care (and careful) means that a person does everything he/she is supposed to do (to prevent an accident). It is the opposite of negligence (and negligent), which makes the responsible person liable for damages to persons injured. If a person "exercises care," a court cannot find him/her responsible for damages from an accident in which he/she is involved. (See: careless)

Copyright © 1981-2005 by Gerald N. Hill and Kathleen T. Hill. All Right reserved.
References in periodicals archive ?
KEYNOTE-240 is a Phase 3, randomized, double-blind trial (, NCT02702401) evaluating Keytruda plus best supportive care compared to placebo plus best supportive care in patients with advanced HCC who were previously treated with systemic therapy.
The company revealed the TAGS (TAS-102 Gastric Study) is a Taiho-sponsored pivotal Phase III multinational, randomised, double-blind study evaluating LONSURF (trifluridine and tipiracil), known as TAS-102, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments.
Of importance, the addition of cetuximab to best supportive care significantly improved median survival compared to best supportive care alone (6.1 versus 4.6 months; hazard ratio, 0.77; 95% confidence interval, 0.64-0.92; P<0.005), and also significantly improved the time to tumour progression (hazard ratio, 0.68; 95% confidence interval, 0.57-0.80; P<0.0001).
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Among patients on cetuximab, 19 (6.6%) had complete or partial responses; none of the patients on best supportive care alone had such improvements.
TAGS (TAS-102 Gastric Study) is a Taiho-sponsored pivotal Phase III, multinational, randomized, double-blind study evaluating trifluridine/tipiracil, also known as TAS-102, plus best supportive care versus placebo plus BSC in patients with metastatic gastric cancer, including gastro esophageal junction cancer, refractory to standard treatments.
"This is the first randomized controlled phase III study comparing a monoclonal antibody with best supportive care in chemoresistant patients," Dr.
The guidelines suggest a number of therapeutic options for ancillary surgery and acceptable regimens in patients whose tumors progress on primary chemotherapy The guidelines' authors note that patients whose tumors progress without clinical benefit on two consecutive, single-agent regimens are unlikely to benefit from additional chemotherapy, and may be offered the best supportive care or entry into a clinical trial.
Current first-line chemotherapy treatment delays progression by approximately six months compared to best supportive care, but median OS remains poor with literature-reported ranges of approximately 10 to 11 months and PFS of approximately six months.
It met its primary endpoint of demonstrating a clinically meaningful and a statistically significant increase in overall survival in the intention-to-treat population of patients treated with fruquintinib plus best supportive care, as compared to patients treated with placebo plus best supportive care.
METIV-HCC was a biomarker-selected, double-blind, placebo-controlled, randomised Phase 3 study that evaluated tivantinib (2:1) against best supportive care in patients with MET-overexpressing, inoperable HCC intolerant to or previously-treated with systemic therapy.
Those unable to tolerate chemotherapy or who have inoperable tumors, require best supportive care.